Literature DB >> 31576499

Early dialysis in a rare case of combined toxic alcohols ingestion.

Carmen Elena Cervantes1, Andrew Chu2, Daniel Heller3, Michael Lemont3.   

Abstract

Ingestion of toxic alcohols (TA) typically presents with a high anion gap (AG) metabolic acidosis, and elevated osmolar gap (OG). Hemodialysis (HD) has not been recommended in early phases of intoxication with high OG and normal AG metabolic acidosis. We describe the case of a 40-year-old male who was brought to our emergency department for reported paint thinner ingestion. He was unable to protect his airway and required intubation. Blood gas showed respiratory acidosis, an initial AG, corrected by albumin of 12.75, lactic acid 5.26 mmol/L, and an OG of 170. Patient was treated with bicarbonate drip, fomepizole and emergent HD, which improved his neurologic status. Days after his admission, alcohol levels came positive for a co-ingestion of ethylene glycol, diethylene glycol, and methanol. Most of the TA are metabolized into their toxic byproducts by the enzyme alcohol dehydrogenase (ADH). The kinetics of these alcohols will be altered when there is co-ingestion of multiple substances. Moreover, early ingestions will translate in a high OG without a high AG. False elevation of lactate can occur with the ingestion of ethylene glycol due to a cross-reaction with L-lactate oxidase in the analyzer. In our case, the administration of fomepizole followed by an early HD given the poor clinical improvement, was followed by a fast recovery of the neurological status and potentially prevented renal failure. A high index of suspicion for TA ingestion should be raised when encountering an individual with lactic acidosis, high OG, and normal AG.

Entities:  

Keywords:  Acid base disorder; Dialysis; Ethylene glycol; Fomepizole; Methanol; Toxic alcohols

Mesh:

Substances:

Year:  2019        PMID: 31576499      PMCID: PMC6990293          DOI: 10.1007/s13730-019-00417-0

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  8 in total

Review 1.  Serum osmolal gap in clinical practice: usefulness and limitations.

Authors:  George Liamis; Theodosios D Filippatos; Angelos Liontos; Moses S Elisaf
Journal:  Postgrad Med       Date:  2017-03-23       Impact factor: 3.840

2.  2015 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd Annual Report.

Authors:  James B Mowry; Daniel A Spyker; Daniel E Brooks; Ashlea Zimmerman; Jay L Schauben
Journal:  Clin Toxicol (Phila)       Date:  2016-12       Impact factor: 4.467

Review 3.  Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Authors:  Vindhya Koppaka; David C Thompson; Ying Chen; Manuel Ellermann; Kyriacos C Nicolaou; Risto O Juvonen; Dennis Petersen; Richard A Deitrich; Thomas D Hurley; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

4.  False elevation of blood lactate reveals ethylene glycol poisoning.

Authors:  Pascal Pernet; Bénédicte Bénéteau-Burnat; Michel Vaubourdolle; Eric Maury; Georges Offenstadt
Journal:  Am J Emerg Med       Date:  2009-01       Impact factor: 2.469

5.  Osmol gaps revisited: normal values and limitations.

Authors:  R S Hoffman; M J Smilkstein; M A Howland; L R Goldfrank
Journal:  J Toxicol Clin Toxicol       Date:  1993

Review 6.  Toxic alcohol ingestions: clinical features, diagnosis, and management.

Authors:  Jeffrey A Kraut; Ira Kurtz
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-28       Impact factor: 8.237

7.  Osmolal and anion gaps in patients admitted to an emergency medical department.

Authors:  L Aabakken; K S Johansen; E B Rydningen; J E Bredesen; S Ovrebø; D Jacobsen
Journal:  Hum Exp Toxicol       Date:  1994-02       Impact factor: 2.903

Review 8.  Antidotes for poisoning by alcohols that form toxic metabolites.

Authors:  Kenneth McMartin; Dag Jacobsen; Knut Erik Hovda
Journal:  Br J Clin Pharmacol       Date:  2016-01-04       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.